RJFSA
SLDB icon

Raymond James Financial Services Advisors’s Solid Biosciences SLDB Stock Holding History

Raymond James Financial Services Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,259
Closed -$177K – 3518
2024
Q1 		$177K Buy
+13,259
New +$124K ﹤0.01% 3129
2020
Q2 		– Sell
-3,333
Closed -$120K – 2897
2020
Q1 		$120K Buy
+3,333
New +$165K ﹤0.01% 2201

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Raymond James Financial Services Advisors's SLDB Position: Q2 2024 in Review

Raymond James Financial Services Advisors sold out of Solid Biosciences (SLDB) in Q2 2024, closing a stake of 13,259 shares — an estimated $177K sold.

Raymond James Financial Services Advisors first reported a position in SLDB in Q1 2020 and held it in 2 quarters. The position peaked at $177K in Q1 2024. 80 funds tracked by Wall St. Rank hold SLDB as of Q2 2024.

  • Raymond James Financial Services Advisors reported no remaining Solid Biosciences position as of Q2 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 13,259 Solid Biosciences shares in Q2 2024, an estimated $177K.
  • Raymond James Financial Services Advisors first reported a position in Solid Biosciences in Q1 2020 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Solid Biosciences position peaked at $177K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2024, filed 19 Jul 2024.